Disappointing trial results for Tetraphase Pharmaceuticals
September 09, 2015 at 14:08 PM EDT
Tetraphase Pharmaceuticals Inc. (Nasdaq: TTPH)
reported disappointing results from an IGNITE2 phase 3 clinical trial
of eravacycline to treat complicated urinary tract infections. The stock price plummeted $35.34 to $9.44.
